

5

METHOD FOR DIAGNOSIS AND THERAPY OF HODGKIN LYMPHOMAS

10 The present invention relates to processes for  
diagnosing and treating Hodgkin's lymphomas  
(lymphogranulomatosis) based on the expression of the  
variant exon v10 of the gene CD44 as the molecular target,  
agents for these processes and the use of these agents.

15 The highly glycosylated cell surface protein CD44 is  
involved in the interaction between cells and the  
extracellular matrix such as migration and activation of  
leukocytes in inflammation and immune monitoring,  
precursor formation of leukocytic and myeloid cells in  
20 bone marrow and also in the development of lymphoid organs  
and the interaction of cells with the extracellular matrix  
(Lesley *et al.*, 1993, Günthert 1993, Pals *et al.*, 1993,  
Mackay *et al.*, 1994). The human CD44 gene is made up of  
at least 19 exons, of which at least 12 which code for the  
25 extracellular region are alternatively spliced (Screaton  
*et al.*, 1992). The CD44 gene is transcribed in a number  
of normal tissues and carcinomas (Fox *et al.*, 1994).  
Whereas the standard CD44 molecule (CD44s) is ubiquitously  
found expressed in epithelial and mesenchymal tissues, the  
30 various isoforms produced by alternative RNA splicing are  
found in very limited distribution (Heider *et al.*, 1993).  
Some of the variant isoforms are involved in the  
activation of lymphocytes and occur in conjunction with  
metastasis (Mackay *et al.*, 1994, Günthert *et al.*,  
35 1991, Rudy *et al.*, 1993, Koopman *et al.*, 1993). Although  
the expression of variant CD44 has been shown to have a

direct biological role in metastasis formation in carcinoma of the pancreas in rats (Günthert *et al.*, 1991, Seiter *et al.*, 1993), its role in human tumours is as yet unknown.

5

Various reports have been published showing that certain alternatively spliced forms of CD44 were expressed in human metastatic tumours (Heider *et al.*, 1993 and 1996, Fox *et al.*, 1994, Friedrichs *et al.*, 1995, Kaufmann *et al.*, 1995, Salles *et al.*, 1993, Stauder *et al.*, 1995, Koopman *et al.*, 1993, Tanabe *et al.*, 1993). Studies of the expression of CD44 in non-Hodgkin's lymphomas (NHL) concentrated on analysing the so-called lymphocyte homing receptor CD44H or CD44s (Horst *et al.*, 1990a, Horst *et al.*, 1990b, Jalkanen *et al.*, 1991, Möller *et al.*, 1992). Whereas some authors (Horst *et al.*, 1990a, Jalkanen *et al.*, 1991, Picker *et al.*, 1988, Pals *et al.*, 1989, Fujiwara *et al.*, 1993) found a correlation between increased CD44s expression and unfavourable prognosis, other authors (Terpe *et al.*, 1994) could not confirm these findings. Recently, upregulation of CD44v3 and CD44v6 isoforms was found in NHL with unfavourable pathological status (Koopman *et al.*, 1993, Terpe *et al.*, 1994, Salles *et al.*, 1993, Stauder *et al.*, 1995), whilst variant specific CD44-mAbs were used (Mackay *et al.*, 1994, Koopman *et al.*, 1993, Fox *et al.*, 1993).

Various approaches have been developed for making use of the differential expression of variant exons of the CD44 gene in tumours and normal tissues for diagnostic and therapeutic purposes (WO 94/02633, WO 94/12631, WO 95/00658, WO 95/00851, EP 0531300).

The aim of the present invention was to develop new methods of diagnosing and treating Hodgkin's lymphomas

(lymphogranulomatosis) and preparing agents for such processes.

5 This aim is achieved by means of the present invention. It relates to processes for diagnosing and treating Hodgkin's lymphomas (lymphogranulomatosis) which are based on the expression of the variant exon v10 of the CD44 gene as a molecular marker or target. Antibody molecules of corresponding specificity are particularly  
10 suitable as vehicles for selectively reaching Hodgkin's lymphomas *in vivo*.

Preferred processes are characterised in that an antibody molecule is used which binds specifically to the  
15 amino acid sequence SEQ ID NO. 2 (see Sequence Listing).

Other aspects of the present invention are the use of antibody molecules of this kind in the processes according to the invention and agents for performing these  
20 processes.

The invention further relates to the use of an antibody molecule which is specific to an epitope within the amino acid sequence which is coded by the variable  
25 exon v10 of the CD44 gene, for preparing a pharmaceutical composition for the diagnosis and/or treatment of tumoral diseases. The tumoral disease in question is preferably Hodgkin's lymphoma (lymphogranulomatosis).

30 The invention further relates to an antibody molecule which is specific to an epitope within the amino acid sequence which is coded by the variable exon v10 of the CD44 gene for pharmaceutical use. Preferably, an antibody molecule of this kind is characterised in that it binds to  
35 SEQ ID NO. 2. It may be, in particular, a monoclonal antibody, an Fab- or F(ab')<sub>2</sub>-fragment of an

immunoglobulin, a recombinantly produced antibody, a recombinantly produced chimeric or humanised antibody or single chain antibody (scFv). Preferably, an antibody molecule of this kind is linked to a radioactive isotope, a radioactive compound, an enzyme, a toxin, a cytostatic, a prodrug, a cytokine or some other immunomodulatory polypeptide.

The nucleic and amino acid sequence of the variant exon v10 of the CD44 gene is known (Screaton *et al.*, 1992, Tölg *et al.*, 1993). These sequences are shown in the Sequence Listing (SEQ ID NO. 1 and 2). The existence of degenerate or allelic variants is unimportant to the performance of the invention; such variants are therefore expressly included.

The invention may be carried out with polyclonal or monoclonal antibodies specific to an epitope which is coded by the exon v10. The preparation of antibodies to known amino acid sequences can be carried out using methods known *per se* (Catty, 1989). For example, a peptide of this sequence may be prepared synthetically and used as an antigen in an immunisation procedure. Another method is to prepare a fusion protein which contains the desired amino acid sequence, by integrating a nucleic acid (which may be prepared synthetically or, for example, by polymerase chain reaction (PCR) from a suitable probe) which codes for this sequence, into an expression vector and expressing the fusion protein in a host organism. The fusion protein, optionally purified, can then be used as an antigen in an immunisation procedure and insert-specific antibodies or, in the case of monoclonal antibodies, hybridomas which express insert-specific antibodies, are selected by suitable methods. Such methods are known in the art. Heider *et al.* (1993, 1996)

and Koopman et al. (1993) describe the preparation of antibodies against variant epitopes of CD44.

However, for the process according to the invention,  
5 it is also possible to use antibody molecules derived from poly- or monoclonal antibodies, e.g. Fab- or F(ab')<sub>2</sub>-fragments of immunoglobulins, recombinantly produced single chain antibodies (scFv), chimeric or humanised antibodies and other molecules which bind specifically to  
10 epitopes coded by exon v10. From a complete immunoglobulin it is possible for example to produce Fab- or F(ab')<sub>2</sub>-fragments or other fragments (Kreitman et al., 1993). The skilled person is also capable of producing recombinant v10-specific antibody molecules.  
15 Corresponding methods are known in the art. Recombinant antibody molecules of this kind may, for example, be humanised antibodies (Shin et al., 1989; Güssow and Seemann, 1991), bispecific antibodies (Weiner et al., 1993; Goodwin, 1989), single chain antibodies (scFv,  
20 Johnson and Bird, 1991), complete or fragmentary immunoglobulins (Coloma et al., 1992; Nesbit et al., 1992; Barbas et al., 1992), or antibodies produced by chain shuffling (Winter et al., 1994). Humanised antibodies may be produced for example by CDR grafting (EP 0239400).  
25 Framework regions may also be modified (EP 0519596). In order to humanise antibodies, nowadays it is possible to use methods such as PCR (cf. for example EP 0368684; EP 0438310; WO 9207075) or computer modelling (cf. for example WO 9222653). It is also possible to prepare and  
30 use fusion proteins such as single chain antibody/toxin fusion proteins (Chaudhary et al., 1990; Friedman et al., 1993). The headings "antibody" and "antibody molecules" should include, in addition to polyclonal and monoclonal antibodies, all the compounds discussed in this section as  
35 well as other compounds which are structurally derived

from immunoglobulins and can be prepared by methods known  
per se.

For diagnostic purposes, antibody molecules may be  
5 linked, for example, to radioactive isotopes such as  $^{131}\text{I}$ ,  
 $^{111}\text{In}$ ,  $^{99\text{m}}\text{Tc}$  or radioactive compounds (Larson et al., 1991;  
Thomas et al., 1989; Srivastava, 1988), enzymes such as  
peroxidase or alkaline phosphatase (Catty and Raykundalia,  
1989), with fluorescent dyes (Johnson, 1989) or biotin  
10 molecules (Guesdon et al., 1979). For therapeutic  
applications, v10-specific antibody molecules may be  
linked to radioisotopes such as  $^{90}\text{Y}$ ,  $^{111}\text{In}$ ,  $^{131}\text{I}$  or  $^{186}\text{Re}$   
(Quadri et al., 1993; Lenhard et al., 1985, Vriesendorp et  
al., 1991; Wilbur et al., 1989), toxins (Vitetta et al.,  
15 1991; Vitetta and Thorpe, 1991; Kreitman et al., 1993;  
Theuer et al., 1993) cytostatics (Schrappe et al., 1992),  
prodrugs (Wang et al., 1992; Senter et al., 1989) or  
radioactive compounds. The antibody may also be linked to  
a cytokine or another immunomodulatory polypeptide, e.g.  
20 tumour necrosis factor or interleukin-2.

Advantageously, the diagnostic process according to  
the invention can be used to examine samples from  
patients, e.g. from biopsies, where there is a suspicion  
25 of Hodgkin's lymphoma (lymphogranulomatosis) or where this  
has already been diagnosed but the tumour requires more  
accurate characterisation. Variant CD44 molecules which  
contain an amino acid sequence coded by the variable exon  
v10 can be detected at the protein level by means of  
30 antibodies or at the nucleic acid level by means of  
specific nucleic acid probes or primers for polymerase  
chain reaction (PCR). The invention consequently also  
relates to antibody molecules and nucleic acids which are  
suitable as probes or primers for such processes, and the  
35 use of these antibodies and nucleic acids for the  
diagnosis and analysis of Hodgkin's lymphomas. For

example, tissue sections can be investigated immunohistochemically with antibodies using methods known *per se*. Extracts or body fluids obtained from tissue samples can also be investigated by other immunological methods using antibodies, e.g. by Western blots, enzyme-linked immunosorbant assays (ELISA, Catty and Raykundalia, 1989), radioimmunoassays (RIA, Catty and Murphy, 1989) or related immunoassays. The samples may be investigated qualitatively, semiquantitatively or quantitatively. The expression of the CD44-splice variant v10 in Hodgkin's disease is associated with aggressive behaviour of the tumour and a high risk of recurrence. This correlates with an advanced stage and poor prognosis of NSHD (nodular sclerosis Hodgkin's disease).

As well as *in vitro* diagnosis, antibody molecules with specificity according to the invention are also suitable for *in vivo* diagnosis of Hodgkin's lymphomas. If the antibody molecule carries a detectable label, the label can be detected for diagnostic purposes, e.g. imaging the tumour *in vivo* or for radioguided surgery, for example. For using antibodies conjugated with radioactive isotopes for immunoscintigraphy (imaging), for example, there are a number of procedures on the basis of which the skilled person can perform the invention (Siccardi et al., 1989; Keenan et al., 1987; Perkins and Pimm, 1992; Colcher et al., 1987; Thompson et al., 1984).

Data obtained by detecting and/or quantifying the expression of the variant CD44 epitope v10 can thus be used for diagnosis and prognosis. It may be advantageous to combine such data with other prognostic parameters, e.g. with the grade of tumour.

Antibody molecules with the specificity according to the invention and optionally linked with a cytotoxic agent

may advantageously be used to treat Hodgkin's lymphomas (lymphogranulomatosis). They may be administered systemically or topically, e.g. by intravenous route (as a bolus or continuous infusion), or by intraperitoneal, intramuscular or subcutaneous injection/infusion. Methods of administering conjugated or non-conjugated antibodies, e.g. complete immunoglobulins, fragments, recombinant humanised molecules etc.) are known in the art (Mulshine et al., 1991; Larson et al., 1991; Vitetta and Thorpe, 1991; Vitetta et al., 1991; Breitz et al., 1992, 1995; Press et al., 1989; Weiner et al., 1989; Chatal et al., 1989; Sears et al., 1982).

The antibody molecules may be formulated in a manner known *per se*. For example, they may be present in aqueous solution, optionally buffered with a physiologically acceptable buffer. A solution of this kind may be characterised by the addition of suitable stabilisers and adjuvants. However, the antibody molecules may also be present in the form of a freeze-dried preparation (lyophilisate) which is reconstituted with a suitable solvent, e.g. water, before use.

In a preferred embodiment of therapeutic application, a humanised v10-specific immunoglobulin or an F(ab')<sub>2</sub>-fragment thereof is linked with <sup>90</sup>Y (Quadri et al., 1993; Vriesendorp et al., 1995), <sup>131</sup>I (Juweid et al., 1995; Press et al., 1995; Thomas et al., in: Catty 1985, p. 230-239), <sup>186</sup>Re (Breitz et al., 1992, 1995) or another suitable radioisotope and used for radioimmunotherapy of Hodgkin's lymphomas. For example, an antibody molecule of this kind may be linked with <sup>90</sup>Y using a chelating linker such as ITCB-DTPA (isothiocyanatobenzyl-diethylenetriamine pentacetate), whilst a specific activity of 5-20 mCi/mg, preferably 10 mCi/mg should be achieved. This agent can then be administered to a patient with an antigen-positive



tumour in a dosage of 0.1 to 1 mCi/kg of body weight, preferably 0.3 to 0.5 mCi/kg of body weight, most preferably 0.4 mCi/kg. When the total quantity of protein to be administered is from 2 to 5 mg this may be given in the form of a rapid intravenous bolus injection. In the case of monoclonal antibodies it may be necessary to mix the agent with an excess (e.g. a ten-fold molar excess) of the non-radioactive antibody before administering it; in this case, the preparation is better administered in the form of an intravenous infusion over a period of 15 minutes, for example. The application can be repeated. The treatment can be backed up by bone marrow transplantation.

005264 04230

### Figures

Fig. 1: A. Individual HRS (Hodgkin and Reed-Sternberg) cells of a patient with no recurrence, reacting with mAb VFF16 (CD44v10). The arrow tips point to non-reactive HRS cells. B. >50% of the HRS cells of patients with a recurrence show reactivity (ABC, x 400).

Fig. 2: CD44v10 expression in HRS cells in various patient groups. It should be noted that patients with a poor clinical progress, i.e. recurrence or bone marrow involvement exclusively show more than 10% positive HRS cells, whereas patients with no recurrence have less 10% positive HRS cells. The difference between these two groups is statistically highly significant.

Fig. 3: RT-PCR analysis using CD44v10-specific primers (right half): the main transcript of about 470 bp in all the probes and a weaker transcript of 660 bp in probes 2, 3 and 4 indicate CD44v10-containing isoforms in all 5 cases. A dominant band of 440 bp when using primers which are specific to the 5'- and 3'-constant region indicates the standard form of CD44 (left half).

## Examples

### Example 1 : Preparation of v10-specific antibodies

5       The entire variant region of the HPKII type of CD44v  
(Hofmann et al., 1991) was amplified from human  
keratinocyte cDNA by polymerase chain reaction (PCR). The  
two PCR primers 5'-CAGGCTGGGAGCCAAATGAAGAAAATG-3',  
positions 25-52, and 5'-TGATAAGGAACGATTGACATTAGAGTTGGA-3',  
10       positions 1013-984 of the LCLC97-variant region as  
described by Hofmann et al. contained an *EcoRI* recognition  
site which was used to clone the PCR product directly into  
the vector pGEX-2T (Smith et al., 1988). The resulting  
construct (pGEX CD44v HPKII, v3-v10) codes for a fusion  
15       protein of ~70 kD, consisting of glutathione-S-transferase  
from *Schistosoma japonicum* and the exons v3-v10 from human  
CD44 (Heider et al., 1993). The fusion protein was  
expressed in *E. coli* and then affinity-purified over  
glutathione-agarose (Smith et al., 1988).

20

Female Balb/c mice were immunised by intraperitoneal  
route with the affinity-purified fusion protein according  
to the following plan:

25       1<sup>st</sup> immunisation: 90 µg of fusion protein in complete  
Freund's adjuvant  
2<sup>nd</sup> and 3<sup>rd</sup> immunisations: 50 µg of fusion protein in  
incomplete Freund's adjuvant.

30       The immunisations were carried out at intervals of 4  
weeks. 14 days after the last immunisation, the animals  
were immunised on three successive days with 10 µg of  
fusion protein in PBS. The next day, spleen cells from an  
animal with a high antibody titre were fused with  
35       P3.X63-Ag8.653 murine myeloma cells using  
polyethyleneglycol 4000. The hybridoma cells were then

selected in microtitre plates in HAT medium (Köhler and Milstein, 1975; Kearney *et al.*, 1979).

5 The antibody titre in the serum and the screening of  
the hybridoma supernatants were carried out using an  
ELISA. In this test, first of all, microtitre plates were  
coated with fusion protein (GST-CD44v3-10) or with  
glutathione-S-transferase on its own. Then they were  
incubated with serial dilutions of serum samples or  
10 hybridoma supernatants and the specific antibodies were  
detected with peroxidase-conjugated antibodies against  
murine immunoglobulin. Hybridomas which reacted only with  
glutathione-S-transferase were discarded. The remaining  
antibodies were characterised first in an ELISA with  
15 domain-specific fusion proteins (exon v3, exon v5 + v6,  
exon v6 + v7, exon v8 - v10, exon v10) (Koopman *et al.*,  
1993). Their immunohistochemical reactivity was tested on  
sections of human skin.

20 Antibodies from the supernatants of the hybridoma  
clones VFF-14 and VFF-16 bind only to fusion proteins  
containing a domain which is coded by the exon v10.

25 **Example 2 : Immunohistochemical examination of tissue  
samples**

Tissue and patients

30 37 Paraffin-embedded lymph node samples from 29  
patients with NSHD (nodular sclerosis Hodgkin's disease;  
according to Rye classification) were obtained from the  
collection of the Pathology Department, University Medical  
School, Graz, Austria, and divided into three groups;  
35 group 1: 11 patients with pretreated NSHD before treatment  
(5 patients at stage I, 6 at stage II), who had been free

from recurrence for more than 6 years; group 2: 9 patients with pretreated NSHD before treatment (4 at stage I, 5 at stage II) suffered a recurrence of the disease in one to three years. Two to three follow-up lymph node sections of NSHD recurrences from 7 of these 9 patients were also included in this study; group 3: 9 patients with bone marrow involvement at the time of the original diagnosis (stage IV).

## 10 Immunohistochemistry

The lymph node samples were stained with the following mAbs: CD44 standard (s) recognised by the mAb SFF2; CD44v5 detected by the mAb VFF8; CD44v6 detected by the mAbs VFF7 and VFF18; CD44v10 detected by the mAbs VFF14 and VFF16. Mab SFF2 recognises an epitope common to all CD44-isoforms. Mabs VFF7 and VFF18 recognise different but overlapping epitopes which are coded by the exon v6. Mab VFF8 is specific to exon v5. Mabs VFF14 and VFF16 react with an epitope which is coded by exon v10.

The immunohistochemistry was carried out on sections treated with microwaves (Gerdes *et al.*, 1992), using the avidin-biotin complex (ABC) peroxidase method (Guesdon *et al.*, 1979). Paraffin sections were dewaxed in xylene, rehydrated and the endogenous peroxidase was blocked with H<sub>2</sub>O<sub>2</sub> in methanol. The slides were placed in a glass stand and wetted in 500 ml of 0.01 M citrate buffer (2.1 g of citric acid in 1 litre of deionised water, pH adjusted to 6.0 using 2 N NaOH). The microwave treatment was carried out for 35 hours at maximum power (600 W) in a microwave oven (BioRad). After 9 minutes' microwave treatment the evaporated buffer was topped up with deionised water. After the microwave irradiation the solution was cooled for 20 minutes. Then the slides were rinsed in phosphate-

buffered saline (PBS) and immunostained by diaminobenzidine (DAB) development.

For comparison, 10 frozen lymph node samples (3 from patients of group 1, 2 from group 2 and 5 recently collected cases) were also incubated with the mAbs VFF14 (v10) and VFF16 (v10), using the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method (Cordell et al., 1984).

10

For control purposes, sections of normal human epidermis which is known to contain the antigens in question were tested (positive controls). Replacement of the primary antibody by normal serum always produced negative results (negative controls).

15

As an additional control, immunohistochemical staining for CD44v10 and CD44v6 expression was repeated twice in each case. To confirm the findings, the cases were additionally incubated in a different laboratory using the APAAP method (Cordell et al., 1984).

20

The percentage of HRS (Hodgkin and Reed-Sternberg) cells stained with the antibodies was graded as 0%, less than 10%, 10-50% and over 50%. Care was taken to ensure that the immunoreactive HRS cells were clearly tumour cells (e.g. by looking for the presence of characteristic nuclear details), particularly in those cases where less than 10% of the HRS cells expressed the antigens in question. All the cases were assessed separately by two of the inventors. The spread of the staining, e.g. on the membrane, in the cytoplasm or both, was recorded, as well as the immunoreactivity in cells which were not HRS cells.

25

30

## Statistical analysis

CD44 expression patterns were analysed using the Pearson-chi-square calculation and the Mantel-Haenszel test for linear association, by means of the program SPSS for Windows. P-values less than or equal to 0.05 were regarded as significant.

## Results of the immunohistochemical staining

Table 1 shows a summary of the results obtained with antibodies directed against CD44s, CD44v5, v6 and v10 in HRS cells. The majority of the antigenic reactivity of the HRS cells was on the cell surface in every case. A variable number of HRS cells yielded cytoplasmic and/or dot-like perinuclear reactivity with or without surface staining, which probably reflected the reactivity of CD44 molecules in the Golgi apparatus or in the endoplasmic reticulum.

*CD44v10 expression correlates with an advanced stage and poor prognosis of NSHD.* CD44s-, CD44v5- (detected by mAb VFF8) and CD44v6-expression (detected by mAb VEF18) in HRS cells was found in the majority of cases, although there was great variation in the number of stained cells (Table 1). CD44v6 expression (detected by mAb VFF7) was found in only a few cases and, when present, was restricted to a minority of HRS cells (Table 1). In patients with no recurrence, CD44v10 expression (detected by the mAbs VFF14 and VFF16) was found in only a very few cases, and the proportion of reactive HRS cells was <10% (Figs. 1A and 2). By contrast, in every case of a patient with a recurrence or initial involvement of the bone marrow, CD44v10 expression was found. In the majority of these cases, there was a clear overexpression of CD44v10 with >50% reactive HRS cells (Figs. 1B and 2). This

overexpression of CD44v10 was also found in the lymph node sections of recurrences studied (Table 2).

Frozen lymph node sections from 3 patients with no recurrence and from 2 patients with a recurrence yielded exactly the same results as paraffin sections. The two antibodies specific to exon v10 (VFF14 and VFF16) showed identical results in the reaction either on the surface and/or in the cytoplasm of the HRS cells.

Using Fisher's exact test, the differences in the CD44 isoform expression between groups of patients with non-aggressive and aggressive NSHD yielded the following p-values: CD44s ( $p=0.3625$ ), CD44v5 ( $p=0.2415$ ), CD44v6 (detected with mAb VFF7) ( $p=0.2903$ ), CD44v6 (detected by mAb VFF18) ( $p=0.1836$ ), CD44v10 (detected by mAbs VFF14 and VFF16) ( $p=0.001$ ). This shows that the different expression patterns of CD44v10 (detected by mAbs VFF14 and VFF16) within these NSHD groups were statistically highly significant. The expression of the CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour of the tumour and a high risk of recurrence. It correlates with an advanced stage and poor prognosis of NSHD.

By contrast with earlier immunohistochemical studies of CD44 expression in conjunction with prognostic relevance in neoplasia of different histogenetic origin, which were carried out exclusively on frozen sections (Koopman *et al.*, 1993, Terpe *et al.*, 1994; Ristamäki *et al.*, 1994, 1995, Stauder *et al.*, 1994, Heider *et al.*, 1993, Horst *et al.*, 1990a,b, Heider *et al.*, 1996, Kaufmann *et al.*, 1995, Mulder *et al.* 1994), the present invention was able to demonstrate that CD44-mAbs can also be used on paraffin-embedded material if microwave treatment is used. This process requires constant fixing and microwave



Exon v10, in addition to exons v3 and v6, is a variant exon which is constitutively expressed in lymphocytes (Stauder et al., 1994). Up till now, CD44v10 expression in NHLs has not been systematically analysed and this exon has only rarely been detected in carcinomas (Heider et al., 1996). The present invention demonstrates, by the example of two different antibodies against CD44v10 (VFF14 and VFF16), a statistically significant high regulation of CD44v10 expression in HRS cells of NSHD with a poor prognosis (groups 2 and 3). Both exon v10-specific antibodies showed identical results, both on the surface and also (and/or) in the

cytoplasm of the HRS cells. The detection of CD44v10 expression with two different mAbs is important because, for example, in breast cancer different data were obtained by different authors using different mAbs of the same exon  
5 specificity (Friedrichs et al., 1995, Kaufmann et al., 1995). To confirm our surprising results still further, all the cases were independently immunostained in a different laboratory (using a different staining method), with identical results.

10

The results for the CD44v10 expression in HRS cells of NSHD are the first data which show a correlation between CD44v10 expression and the stage and prognosis of the disease. The methods according to the invention thus  
15 provide the doctor with valuable diagnostic and prognostic information on Hodgkin's lymphoma. Moreover, CD44v10 is a suitable molecular target for therapeutic interventions in this disease.

40052641 012202

Table 1 : Reactivity of HRS cells

Patients	%	CD44s SFF2	v5 VFF8	v6 VFF7	v6 VFF18	v10 VFF14	v10 VFF16
Group 1							
n = 11		n %	n %	n %	n %	n %	n %
	> 50	3 27.3	0 0	0 0	1 9.1	0 0	0 0
	10-50	3 27.3	1 9.0	0 0	0 0	0 0	0 0
	< 10	3 27.3	6 54.5	2 18.2	8 72.7	4 36.4	4 36.4
	0	2 18.1	4 36.5	9 81.8	2 18.2	7 63.6	7 63.6
Group 2							
n = 9		n %	n %	n %	n %	n %	n %
	> 50	2 22.2	1 11.1	0 0	1 11.0	4 44.4	4 44.4
	10-50	5 55.6	1 11.1	1 11.1	4 44.5	5 55.6	5 55.6
	< 10	2 22.2	7 77.8	3 33.3	4 44.5	0 0	0 0
	0	0 0	0 0	5 55.6	0 0	0 0	0 0
Group 3							
n = 9		n %	n %	n %	n %	n %	n %
	> 50	0 0	0 0	0 0	0 0	5 55.6	5 55.6
	10-50	6 66.7	1 11.1	1 11.1	2 22.2	4 44.4	4 44.4
	< 10	3 33.3	8 88.9	0 0	7 77.8	0 0	0 0
	0	0 0	0 0	8 88.9	0 0	0 0	0 0

**Table 2: Reactivity (%) of CD44v10 (VFF14 and VFF16) and CD44v6 (VFF18) in HRS cells of patients of group 2 (recurrence)**

Patients	CD44v10 (VFF14)	CD44v10 (VFF16)	CD44v6 (VFF18)
1	>50	>50	10 - 50
1 recurrence	10 - 50	10 - 50	10 - 50
1 recurrence	10 - 50	10 - 50	10 - 50
2	>50	>50	10 - 50
2 recurrence	10 - 50	10 - 50	10 - 50
3	10 - 50	10 - 50	<10
3 recurrence	10 - 50	10 - 50	<10
4	10 - 50	10 - 50	<10
4 recurrence	10 - 50	10 - 50	>50
5	10 - 50	10 - 50	10 - 50
5 recurrence	10 - 50	10 - 50	10 - 50
6	>50	>50	<10
6 recurrence	>50	>50	10 - 50
7	>50	>50	<10
7 recurrence	10 - 50	10 - 50	<10
8	10 - 50	10 - 50	10 - 50
9	10 - 50	10 - 50	>50

### Example 3: Use of v10-specific RT-PCR for diagnostic purposes

Reverse transcription polymerase chain reaction (PCR)

5

Five cases enabled mRNA to be isolated and were additionally analysed by reverse transcriptase polymerase chain reaction (RT-PCR).

10

1 µg of total RNA was isolated and reverse transcribed as described in the literature (Günthert et al., 1991). 5 µl of first strand cDNA were amplified with Taq polymerase (Promega, Madison, USA) in a volume of 50 µl, using the buffer conditions recommended by the manufacturer. The concentration of primer was 0.2 mM. In order to test the quality and frequency of cDNA synthesis, a GAPDH-PCR was carried out with oligonucleotides which were homologous to positions 8 - 29 and 362 - 339 of the published GAPDH-cDNA sequence (Allen et al., 1987). Pre-incubation for 5 minutes at 95°C was followed by 25 amplification cycles (30 seconds at 95°C, 1.5 minutes at 62°C) and an extension cycle of 7 minutes at 72°C. Then 10 µl of the reaction were analysed on a 2% agarose gel and the amplification product was inspected under UV light after the gel had been stained with ethidium bromide. In order to amplify cDNAs containing CD44v10, primers were used which were homologous with the 3'-end of exon v10 (positions 986-1013, Hofmann et al., 1991) and with the 5'-constant region of CD44 (positions 513-540, Stamenkovic et al., 1989). In order to amplify isoforms containing CD44 standard, a 3'-constant CD44 primer (positions 934-958, Stamenkovic et al., 1989) was used instead of the CD44v10-specific primer. After 40 amplification cycles (94°C for 30 seconds, 62°C for 1.5 minutes), 10 µl of the reaction mixture were analysed as above. For control purposes, instead of RNA, either distilled water was used

35

(negative control) or a plasmid containing CD44v3-v10 was used (positive control, Heider *et al.*, 1996).

In the 5 cases in which it was possible to isolate RNA, the RT-PCR analysis confirmed the expression of CD44v10 containing CD44-isoforms (as they were samples which had only recently been obtained, the further progress of the disease in these patients is not yet known). The amplified fragments correspond to CD44 transcripts which contain the constant proportion of CD44 combined with the variant exon v10 (460 bp band) or variant exon v10 plus other variant exons (660 bp band) (Fig. 3, right half). For control purposes, parallel cDNAs were amplified with primers which were specific for the 5'- and 3'-constant region of CD44 (Fig. 3, left hand side), obtaining a prominent band of 440 bp which indicates the standard form of CD44. The molecular-genetic results correlated with the immunohistochemical findings, where in all 5 cases a high proportion of the HRS cells (which represented less than 10% of the total number of cells in a sample) expressed CD44v10 and the majority of the cells (HRS plus non-tumour cells) reacted with the anti-CD44s antibody.

### Literature

- Allen RW, Trach KA, Hoch JA. Identification of the 37-kDa protein displaying a variable interaction with the erythroid cell membrane as glyceraldehyde-3-phosphate dehydrogenase. *J. Biol. Chem.* 262 (2): 649-653 (1987).
- Barbas C F, Björling E, Chiodi F, Dunlop N, Cababa D, Jones T M, Zebedee S L, Persson M A A, Nara P L, Norrby E, Burton D R. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus *in vitro*. *Proc. Natl. Acad. Sci. USA.* 89: 9339-9343 (1992).
- Breitz H B, Weiden P L, Vanderheyden J-L, Appelbaum J W, Bjorn M J, Fer M F, Wolf S B, Ratcliff B A, Seiler C A, Foisie D C, Fisher D R, Schroff R W, Fritzberg A R, Abrams P G. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. *J. Nucl. Med* 33: 1099-1112 (1992).
- Breitz H B, Durham J S, Fisher D R, Weiden P L, DeNardo G L, Goodgold H M, Nelp WB. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. *J. Nucl. Med* 36: 754 (1995).
- Catty, D (Editor). *Antibodies Vols. I and II*. IRL Press Oxford (1989).
- Catty, D., Raykundalia, C. ELISA and related immunoassays. In: Catty, D (Editor). *Antibodies Vol. II*. IRL Press Oxford (1989), 97-152, see pages 105-109.
- Catty, D., Murphy, G. Immunoassays using radiolabels. In: Catty, D (Ed.). *Antibodies Vol. II*. IRL Press Oxford (1989), 77-96.

Chatal J-F, Saccavini J-C, Gestin J-F, Thédrez P, Curtet  
C, Kremer M, Guerreau D, Nolibé D, Fumoleau P, Guillard Y.  
Biodistribution of indium-111-labeled OC 125 monoclonal  
antibody intraperitoneally injected into patients operated  
5 on for ovarian carcinomas. *Cancer Res.* 49: 3087-3094  
(1989).

Chaudhary V K, Batra J K, Galdo M G, Willingham M C,  
Fitzgerald D J, Pastan I. A rapid method of cloning  
10 functional variable-region antibody genes in *Escherichia*  
*coli* as single-chain immunotoxins. *Proc. Natl. Acad Sci.*  
*U.S.A.* 87: 1066 (1990).

Colcher D, Esteban J, Carrasquillo J A, Sugarbaker P,  
15 Reynolds J C, Bryant G, Larson S M, Schlom J.  
Complementation of intracavitary and intravenous  
administration of a monoclonal antibody (B72.3) in  
patients with carcinoma. *Cancer Res.* 47: 4218-4224 (1987).

20 Coloma M J, Hastings A, Wims L A, Morrison S L. Novel  
vectors for the expression of antibody molecules using  
variable regions generated by polymerase chain reaction.  
*J. Immunol. Methods* 152: 89-104 (1992). -

25 Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z,  
MacDonald S, Pulford KA, Stein H, Mason DY.  
Immunoenzymatic labeling of monoclonal antibodies using  
immune complexes of alkaline phosphatase and monoclonal  
anti-alkaline phosphatase (APAAP complexes). *J. Histochem.*  
30 *Cytochem.* 32 (2): 219-229 (1984).

Fox SB, Gatter KC, Jackson DG, Screaton GR, Bell MV, Bell  
JI, Harris AL, Simmons D, Fawcett J. CD44 and cancer  
screening. *Lancet* 342 (8870): 548-549 (1993).



Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KG, Harris AL, Gearing A, Simmons DI. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. *Cancer Res* 54: 4539-4546 (1994)

5

Friedmann P N, McAndrew S J, Gawlak S L, Chace D, Trail P A, Brown J P, Siegall C B. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. *Cancer Res.* 53: 334-339 (1993).

10

Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Holzel F, Maass H, Günthert U. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. *Cancer Res.* 55(22):

15

5424-5433 (1995).

Fujiwara K, Yoshino T, Miyake K, Ohara N, Akagi T. Expression of a lymphocyte adhesion molecule (CD44) in malignant lymphomas: relevance to primary site, histological subtype and clinical stage. *Acta Med. Okayama* 47 (3): 215-222 (1993).

20

Gerdes J, Becker MH, Key G, Cattoretti G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. *J. Pathol.* 168 (1): 85-86 (1992).

25

Goodwin D A. A new approach to the problem of targeting specific monoclonal antibodies to human tumors using anti-hapten chimeric antibodies. *J. Nucl. Med. Biol.* 16: 645 (1989).

30

Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Haußmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P. A new variant of glycoprotein CD44 confers

35

metastatic potential to rat carcinoma cells. *Cell* 65:  
13-24 (1991).

5 Günthert U. CD44: a multitude of isoforms with diverse  
functions. *Curr. Top. Microbiol. Immunol* 184: 47-63  
(1993).

10 Guesdon, J. I., Ternynck, T., Avrameas, S. *J. Histochem.  
Cytochem.* 27: 1131 (1979).

Güssow D, Seemann G. Humanization of monoclonal  
antibodies. *Methods Enzymol.* 203: 99-121 (1991):

15 Heider, K.-H., Hofmann, M., Horst, E., van den Berg, F.,  
Ponta, H., Herrlich, P., and Pals, S.T.A human homologue  
of the rat metastasis-associated variant of CD44 is  
expressed in colorectal carcinomas and adenomatous polyps.  
*J. Cell Biol.* 120: 227-233 (1993).

20 Heider, K.-H., Mulder, J.-W. R., Ostermann, E., Susani,  
S., Patzelt, E., Pals, S.T., Adolf, G.R. Splice variants  
of the cells surface glycoprotein CD44 associated with  
metastatic tumor cells are expressed in normal tissues of  
humans and cynomolgus monkeys. *Eur. J. Cancer* 31A:  
25 2385-2391 (1995).

Heider K H, Ratschek M, Zatloukal K, Adolf G R. Expression  
of CD44 isoforms in human renal cell carcinomas. *Virchows  
Arch.* 428: 267-273 (1996).

30 Hofmann, M., Rudy, W., Zöllner, M., Tölg, C., Ponta, H.,  
Herrlich P., and Günthert, U. CD44 splice variants confer  
metastatic behavior in rats: homologous sequences are  
expressed in human tumor cell lines. *Cancer Res.* 51:  
35 5292-5297 (1991).

Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van  
Krieken JH, Pals ST. Adhesion molecules in the prognosis  
of diffuse large-cell lymphoma: expression of a  
lymphocyte homing receptor (CD44), LFA-1 (CD 11a/18), and  
5 ICAM-1 (CD54). *Leukemia* 4 (8): 595-599 (1990a).

Horst E, Meijer CJ, Radaskiewicz T, van Dongen JJ, Pieters  
R, Figdor CG, Hooftman A, Pals ST. Expression of a human  
homing receptor (CD44) in lymphoid malignancies and  
10 related stages of lymphoid development. *Leukemia* 4(5):  
383-389 (1990b).

Jalkanen S, Joensuu H, Soderstrom KO, Klemi P. Lymphocyte  
homing and clinical behavior of non-Hodgkin's lymphoma. *J.*  
15 *Clin. Invest.* 87 (5): 1835-1840 (1991).

Johnson, G D. Immunofluorescence. In: Catty, D (Ed.).  
*Antibodies Vol. II.* IRL Press Oxford (1989), 179-200, see  
pages 180-189.

20 Johnson S, Bird R E. Construction of single-chain  
derivatives of monoclonal antibodies and their production  
in *Escherichia coli*. *Methods Enzymol.* 203: 88-98 (1991).

25 Juweid M, Sharkey R M, Markowitz A, Behr T, Swayne L C,  
Dunn R, Hansen H J, Shevitz J, Leung S-O, Rubin A D,  
Herskovic T, Hanley D, Goldenberg D M. Treatment of  
Non-Hodgkins's lymphoma with radiolabeled murine,  
chimeric, or humanized LL2, an anti-CD22 monoclonal  
30 antibody. *Cancer Res. (Suppl.)* 55: 5899s-5907s (1995).

Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H,  
Herrlich P. CD44 variant exon epitopes in primary breast  
cancer and length of survival. *Lancet* 345 (8950): 615-619  
35 (1995).

Kearney, J.F, Radbruch A., Liesegang B., Rajewski K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits construction of antibody-secreting hybrid cell lines. *J. Immunol.* 123: 1548 (1979).

5

Keenan A M, Weinstein J N, Carrasquillo J A, Bunn P A, Reynolds J C, Foon K A et al. Immunolymphoscintigraphy and the dose dependence of <sup>111</sup>In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma.

10 *Cancer Res.* 47: 6093-6099 (1987).

Köhler, G., Milstein, C. Continuous culture of fused cells secreting antibody of predefined specificity. *Nature* 265: 495 (1975)

15

Koopman, G, Heider, K.-H., Horts, E., Adolf, G. R., van den Berg, F., Ponta, H., Herrlich, P. Pals. S.T. Activated human lymphocytes and aggressive Non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated

20 variant of CD44. *J. Exp. Med* 177: 897-904 (1993).

Kreitman R J Hansen H J, Jones A L, FitzGerald D J P, Goldenberg D M, Pastan I. *Pseudomonas* exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab'

25 induce regression of subcutaneous human B-cell lymphoma in mice. *Cancer Res.* 53: 819-825 (1993).

Larson S M, Cheung N-K V, Leibel S A. Radioisotope Conjugates. In: DeVita V T, Hellman S, Rosenberg S A

30 (Eds.). *Biological therapy of cancer.* J. B. Lippincott Comp., Philadelphia, 496-511(1991).

Lenhard R E, Order S E, Spunberg J J, Asbell S O, Leibel S A. Isotopic immunoglobulin. A new systemic therapy for

35 advanced Hodgkin's Disease. *J. Clin. Oncol.* 3: 1296-1300 (1985).

Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. *Adv. Immunol.* 54: 271-335 (1993).

5

Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. *J. Cell. Biol.* 124 (1-2): 71-82 (1994).

10

Möller P, Eichelmann A, Mechtersheimer G, Koretz K. Expression of beta 1-integrins, H-CAM (CD44) and LECAM-1 in primary gastro-intestinal B-cell lymphomas as compared to the adhesion receptor profile of the gut-associated lymphoid system, tonsil and peripheral lymph node. *Int. J. Cancer* 49 (6): 846-855 (1991).

15

Möller P, Eichelmann A, Leithauser F, Mechtersheimer G, Otto HF. Venular endothelium binding molecules CD44 and LECAM-1 in normal and malignant B-cell populations. A comparative study. *Virchows Arch. (A)* 421 (4): 305-313 (1992).

20

Mulder JWR, Kruyt PHM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ, Pals ST. Expression of exon v6 containing CD44 proteins in human colorectal cancer is associated with unfavorable prognosis in long term follow up. *Lancet* 344: 1470-1472 (1994).

25

Mulshine J L, Magnani J L, Linnoila R I: Applications of monoclonal antibodies in the treatment of solid tumors. In: DeVita V T, Hellman S, Rosenberg S A (Eds.). *Biological therapy of cancer*. J. B. Lippincott Comp., Philadelphia, 563-588 (1991).

35

20250714 14:44:00

Nesbit M, Fu Z F, McDonald-Smith J, Steplewski Z, Curtis P  
J. Production of a functional monoclonal antibody  
recognizing human colorectal carcinoma cells from a  
baculovirus expression system. *J. Immunol. Methods* 151:  
5 201-208 (1992).

Pals ST, Horst E, Ossekopppele GJ, Figdor CG, Scheper RJ,  
Meijer CJ. Expression of lymphocyte homing receptor as a  
mechanism of dissemination in non-Hodgkin's lymphoma.  
10 *Blood* 73 (4): 885-888 (1989).

Pals ST, Koopman G, Griffioen A, et al. A variety of  
isoforms with functions in cell adhesion and tumor  
metastasis, in Shimiziu (Ed.): Lymphocyte adhesion  
15 molecules, Austin, Texas, R. G. Landes Comp., 1993, p 135.

Perkins A C, Pimm M V. A role for gamma scintigraphy in  
cancer immunology and immunotherapy. *Eur. J. Nucl. Med* 19:  
20 1054-1063 (1992).

Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC.  
Expression of lymphocyte homing receptor antigen in  
non-Hodgkin's lymphoma. *Am. J. Pathol.* 130 (3): 496-504  
(1988).

Press O W, Eary J F, Badger C C, Martin P J, Appelbaum F  
R, Levy R, Miller R, Brown S, Nelp W B, Krohn K A, Fisher  
D, DeSantes K, Porter B, Kidd P, Thomas E D, Bernstein I  
25 D. Treatment of refractory Non-Hodgkin's lymphoma with  
30 radiolabeled MB-1 (anti-CD37) antibody. *J. Clin. Oncol.* 7:  
1027-1038 (1989).

Press O W, Eary J F, Appelbaum F R, Martin P J, Nelp W B  
Glenn S, Fisher D J, Porter B, Matthews D C Gooley T,  
35 Bernstein I D. Phase II trial of <sup>131</sup>I-B1 (anti-CD20)

antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. *Lancet* 346: 336-340 (1995).

- 5 Quadri S M, Vriesendorp H M, Leichner P K, Williams J R.  
Evaluation of indium- 111 and yttrium-90 labeled linker  
immunoconjugates in nude mice and dogs. *J. Nucl. Med* 34:  
938-945 (1993).
- 10 Ristamaki R, Joensuu H, Salmi M, Jalkanen S. Serum CD44 in  
malignant lymphoma: an association with treatment  
response. *Blood* 84 (1): 238-243 (1994).
- 15 Ristamaki R, Joensuu H, Soderstrom KO, Jalkanen S. CD44v6  
expression in non-Hodgkin's lymphoma: an association with  
low histological grade and poor prognosis. *J. Pathol.* 176  
(3): 259-267 (1995).
- 20 Rudy W, Hofmann M, Schwartz-Albiez R, Zoller M, Heider KH,  
Ponta H, Herrlich P. The two major CD44 proteins expressed  
on a metastatic rat tumor cell line are derived from  
different splice variants: each one individually suffices  
to confer metastatic behavior. *Cancer Res.* 53 (6):  
1262-1268 (1993).
- 25 Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA.  
Alternatively spliced CD44 transcripts in diffuse  
large-cell lymphomas: characterization and comparison with  
normal activated B cells and epithelial malignancies.  
*Blood* 82 (12): 3539-3547 (1993).
- 30 Sambrook, J., Fritsch E.E., Maniatis I., *Molecular  
cloning*. Cold Spring Harbor Laboratory Press, Cold Spring  
Harbor (1989).
- 35 Schrappe M, Bumol T F, Apelgren L D, Briggs S L, Koppel G  
A, Markowitz D D, Mueller B M, Reisfeld R A. Long-term

growth suppression of human glioma xenografts by  
chemoimmunoconjugates of 4-desacetylvinblastine-  
3-carboxyhydrazide and monoclonal antibody 9.2.27. *Cancer*  
*Res.* 52: 3838-3844 (1992).

5

Screaton, G.R., Bell, M.V., Jackson, D.G., Cornelis, F.B.,  
Gerth, U., and Bell, J. I. Genomic structure of DNA  
encoding the lymphocyte homing receptor CD44 reveals at  
least 12 alternatively spliced exons. *Proc. Natl. Acad*  
10 *Sci. U.S.A.* 89: 12160-12164 (1992).

Sears H F, Mattis J, Herlyn D, Häyry P, Atkinson B, Ernst  
C, Steplewski Z, Koprowski H. Phase-I clinical trial of  
monoclonal antibody in treatment of gastrointestinal  
15 tumours. *Lancet* 1982 (1): 762-765 (1982).

Seiter, S, Arch, R., Reber, S., Komitowski, D., Hofmann,  
M., Ponta, H., Herrlich, P., Matzku, S., Zöller, M.  
Prevention of tumor metastasis formation by anti-variant  
20 CD44. *J. Exp. Med.* 177: 443-455 (1993).

Senter P D, Schreiber G J, Hirschberg D L, Ashe S A,  
Hellström K E, Hellström I. Enhancement of the *in vitro*  
and *in vivo* antitumor activities of phosphorylated  
25 mitomycin C and etoposide derivatives by monoclonal  
antibody-alkaline phosphatase conjugates. *Cancer Res.* 49:  
5789-5792 (1989).

Shin S-U, Morrison S L. Production and properties of  
30 chimeric antibody molecules. *Methods Enzymol.* 178: 459-476  
(1989).

Siccardi A G, Buraggi G L, Callegaro L, Colella A C,  
DeFilippi P G et al. Immunoscintigraphy of adenocarcinomas  
35 by means of radiolabeled F(ab')<sub>2</sub> fragments of an



anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. *Cancer Res.* 49: 3095-3103 (1989).

5 Smith, DB., Johnson, K.S. Single-step purification of polypeptides expressed in *Escherchia coli* as fusions with glutathione S-transferase. *Gene* 67: 31 (1988).

10 Srivastava S C (Ed.). Radiolabeled monoclonal antibodies for imaging and therapy. *Life Sciences Series A* 152, Plenum New York (1988).

15 Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. *Cell* 56 (6): 1057-1062 (1989).

20 Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. *Blood* 85 (10): 2885-2899 (1995).

Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. *Lancet* 341 (8847): 725-726 (1993).

25 Terpe HJ, Stark H, Prehm P, Günthert U. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. *Histochemistry* 101(2): 79-89 (1994).

30 Theuer C P, Kreitman R J, FitzGerald D J, Pastan I. Immunotoxins made with a recombinant form of *pseudomonas* exotoxin A that do not require proteolysis for activity. *Cancer Res.* 53: 340-347 (1993).

35 Thomas, G D., Dykes, P. W., Bradwell, A. R. Antibodies for tumour immunodetection and methods for antibody

radiolabeling. In: Catty, D. (Ed.). *Antibodies Vol. II*. IRL Press Oxford, 223-244 (1989).

- Thompson C H, Stacker S A, Salehi N, Lichtenstein M,  
5 Leyden M J, Andrews J T. Immunoscintigraphy for detection  
of lymph node metastases from breast cancer. *Lancet* 1984  
(2): 1245-1247 (1984).

- Tölg, C., Hofmann, M., Herrlich, P., and Ponta, H.  
10 Splicing choice from ten variant exons establishes CD44  
variability. *Nucleic Acids. Res.* 21: 1225-1229 (1993).

- Vitetta E S, Thorpe P E. *Immunotoxins*. In: DeVita V T,  
Hellman S, Rosenberg S A (Eds.). *Biological therapy of*  
15 *cancer*. J. B Lippincott Comp., Philadelphia, 482-495  
(1991).

- Vitetta E S, Stone M, Amlot P, Fay J, May R, Till M,  
Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr  
20 J W, Thorpe P E. Phase I immunotoxin trial in patients  
with B-cell lymphoma. *Cancer Res.* 51: 4052-4058 (1991).

- Vriesendorp H M, Herbst J M, Germack M A, Klein J L,  
Leichner P K, Loudenslager D M, Order S E. Phase I-II  
25 studies of yttrium-labeled antiferritin treatment for end  
stage Hodgkin's disease, including Radiation Therapy  
Oncology Group 87-01. *J. Clin Oncol.* 9: 918-928 (1991).

- Vriesendorp H M, Morton J D, Quadri S M. Review of five  
30 consecutive studies of radio-labeled immunoglobulin  
therapy in Hodgkins's Disease. *Cancer Res. (Suppl.)* 55:  
5888s-5892s (1995).

- Wang S-M, Chern J-W, Yeh M-Y, Ng J C, Tung E, Roffler S R.  
35 Specific activation of glucuronide prodrugs by

antibody-targeted enzyme conjugates for cancer therapy.  
*Cancer Res.* 52: 4484-4491 (1992).

- 5 Weiner L M, O'Dwyer J, Kitson J, Comis R L, Frankel A E,  
Bauer R J, Kopnrad M S, Groves E S. Phase I evaluation of  
an anti-breast carcinoma monoclonal antibody 260F9-  
recombinant ricin A chain immunoconjugate. *Cancer Res.* 49:  
4062-4067 (1989).
- 10 Weiner LM, Holmes M, Adams GP, LaCreta V, Watts P, Garcia  
de Palazzo I. A human tumor xenograft model of therapy  
with a bispecific monoclonal antibody targeting c-erbB-2  
and CD16. *Cancer Res.* 53 (1): 94-100 (1993).
- 15 Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP,  
Hsieh-Ma ST, Ring DB, Alpaugh RK. Binding and cytotoxicity  
characteristics of the bispecific murine monoclonal  
antibody 2B1. *J. Immunol.* 151 (5): 2877-2886 (1993).
- 20 Wilbur, D S., Hadley, S. W., Hylarides, M D., Abrams, P.  
G., Beaumier, P. A., Morgan, A.C., Reno, J.M., Fritzberg,  
AR. Development of a stable radioiodinating agent to label  
monoclonal antibodies for radiotherapy of cancer. *J. Nucl.*  
*Med.* 30: 216-226 (1989).
- 25 Winter, G., Griffith, A. D., Hawkins, R. E., Hoogenboom,  
H. R. Making antibodies by phage display technology. *Ann.*  
*Rev. Immunol.* 12, 433-455 (1994).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(1) APPLICANT:

(A) NAME: Boehringer Ingelheim International GmbH

(B) STREET: Rheinstrasse

(C) TOWN: Ingelheim

(E) COUNTRY: Germany

(F) POST CODE: 55216

(G) TELEPHONE: 06132-77-2770

(H) TELEFAX: 06132-77-4377

(ii) TITLE OF INVENTION: Process for diagnosis and therapy of lymphogranulomatosis

(iii) Number of Sequences: 4

(iv) COMPUTER-READABLE FORM:

(A) DATA CARRIER: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EP0)

(2) DATA ON SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 Base pairs

(B) TYPE: Nucleotide

(C) STRAND FORM: both

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: Genome-DNA

5 (ix) FEATURE

(A) NAME/CODE: exon

10 (B) POSITION:1. .204

(D) OTHER INFORMATION:/product= "Exon v10 of human CD44"  
/note= "GenBank accession no. L05419"

15 /citation= ([1])

(ix) FEATURE:

20 (A) NAME/CODE: CDS

(B) POSITION:3. .203

25 (x) INFORMATION ON PUBLICATION:

(A) AUTHORS: Screaton, GR

Bell, MV

30 Jackson, DG

Cornelis, FB

35 Gerth, U

Bell, JI

40 (B) TITLE: Genomic structure of DNA encoding the lymphocyte homing  
receptor CD44 reveals at least 12 alternatively spliced exons

(C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A.

(D) VOLUME: 89

45 (F) PAGES: 12160 12164

(G) DATE: December-1992

50 (K) SIGNIFICANT GROUPS IN SEQ ID NO: 1: From 1 to 204

(xi) SEQUENCE LISTING: SEQ ID NO: 1:

(2) DATA ON SEQ ID NO: 2:

30 (A) LENGTH: 67 amino-acids  
(B) TYPE: amino-acid  
(D) TOPOLOGY: linear

(xi) SEQUENCE LISTING: SEQ ID NO: 2:

```

40      Arg Asn Asp Val Thr Gly Gly Arg Arg Asp Pro Asn His Ser Glu Gly
        1              5              10              15

45      Ser Thr Thr Leu Leu Glu Gly Tyr Thr Ser His Tyr Pro His Thr Lys
        20              25              30

        Glu Ser Arg Thr Phe Ile Pro Val Thr Ser Ala Lys Thr Gly Ser Phe
        35              40              45

50

        Gly Val Thr Ala Val Thr Val Gly Asp Ser Asn Ser Asn Val Asn Arg
        50              55              60

```

Ser Leu Ser  
65

5 (2) DATA ON SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 27 Base pairs

(B) TYPE: Nucleotide

15 (C) STRAND FORM: Single strand

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: Other Nucleic acid

20

(A) DESCRIPTION: /desc = "PCR Primer"

(xi) SEQUENCE LISTING: SEQ ID NO: 3:

25

CAGGCTGGGA GCCAAATGAA GAAAATG

27

(2) DATA ON SEQ ID NO: 4:

30

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 Base pairs

35 (B) TYPE: Nucleotide

(C) STRAND FORM: Single strand

(D) TOPOLOGY: linear

40

(ii) TYPE OF MOLECULE: Other Nucleic acid

(A) DESCRIPTION: /desc = "PCR primer"

45

(xi) SEQUENCE LISTING: SEQ ID NO: 4:

TGATAAGGAA CGATTGACAT TAGAGTTGGA

30

10052644.04300